Press release
The Psoriasis Drugs Market to Ride on Medical Coding Software
Psoriasis is a chronic inflammatory skin disease that occurs due to genetic disposition and environmental factors. Psoriasis is a systemic disease associated with psychological, metabolic, arthritic, and cardiovascular comorbidities. On an average, psoriasis affects around 2 - 3% of the population globally.
Plaque psoriasis, being the number one and most common indication, held nearly 85% share of the US$ 11.37 Bn psoriasis drugs market in 2021, with the market estimated to expand at a CAGR of nearly 6.5% over the next ten years.
An array of agents exist for the symptomatic treatment of psoriasis. Patients with mild-to-moderate psoriasis typically receive topical treatments that modulate gene transcription, promote keratinocyte differentiation, and inhibit cell proliferation.
Planning Forward? Access Sample Of Psoriasis Drugs Market Report! https://www.persistencemarketresearch.com/samples/25102
A number of innovative and advanced therapies for the treatment and management of psoriasis are under development, many of which have novel targets and mechanisms of action. Psoriasis is linked with a number of medical conditions inclusive of psoriatic arthritis, depression, and cardio metabolic syndrome. The most commonly occurring form of psoriasis is chronic plaque.
Common treatment methods of psoriasis include topical administration of vitamin D analogues, glucocorticoids, and phototherapy. Moderate to severe psoriasis often calls for systemic treatment.
Prevalence of psoriasis has displayed a growing trend over the past decade. Rising awareness initiatives regarding psoriasis disease and its management & treatment options, increasing reimbursement support, and growing research & development with the adoption of biologics and biosimilars are some of the factors responsible for impacting the psoriasis drugs market and aiding sales growth.
Company Profiles:
Janssen Biotech, Inc.
Novartis International Ltd.
Amgen Inc
Pfizer Inc.
Takeda Pharmaceutical Company Ltd.
Merck & Co, Inc.
Abb Vie Inc.
Eli Lilly and Company
Boehringer Ingelheim GmbH
Sun Pharmaceutical Industries Ltd
How About Revitalizing The Strategy-Oriented Funnel To Stay Ahead In The Psoriasis Drugs Market? https://www.persistencemarketresearch.com/methodology/25102
Key Takeaways from Market Study
Topical products are expected to continue holding over one-third market value share through 2031, primarily because of clinically approved topical ointments, foams, and creams available for the management of inflammation and rash due to psoriasis.
Efficiency of corticosteroids for skin irritability and inflammation makes corticosteroid the leading segment with over 34% of revenue share in 2021.
Easy availability of psoriasis drugs in hospital pharmacies and large distribution networks of hospital chains make it the largest segment, with more than 39% market share.
Plaque psoriasis is the most commonly occurring autoimmune disease, accounting for a revenue share of around 85% in 2021.
Presence of a large number of manufacturers, rising public awareness, and easy availability of psoriasis drugs and treatment options make North America the leading regional market with over 27% market share in 2021.
"Growing adoption of combination therapy and favourable reimbursement support for psoriasis to drive market growth," says an analyst of Persistence Market Research.
Planning To Introduce An Offbeat Product/Technology In The Psoriasis Drugs Market? Go To "Purchase Now" To Have Our Psoriasis Drugs Market Report! https://www.persistencemarketresearch.com/checkout/25102
Market Competition
Companies such as Amgen and Sun Pharma have been strongly working toward the development of an extensive clinical pipeline and manufacturing of new product lines for the treatment of psoriasis.
In December 2021, Amgen announced positive top-line results from the Otezla® (apremilast) Phase 3 DISCREET study in moderate to severe genital psoriasis.
In September 2020, Sun Pharma announced the launch of ILUMYA® (tildrakizumab) for the treatment of plaque psoriasis, in Japan.
Similarly, other psoriasis drug manufacturers are also trying to maintain and strengthen their portfolios through collaborations with local players or distribution partners. All such recent developments related to companies manufacturing psoriasis drugs have been tracked by the team at Persistence Market Research, which are available in the full report.
Key companies operating in the psoriasis drugs market include Janssen Biotech Inc, Novartis International Ltd., Amgen Inc, Pfizer Inc., Takeda Pharmaceutical Company Ltd. Merck & Co, Inc., Abb Vie Inc., Eli Lilly and Company, Boehringer Ingelheim GmbH, and Sun Pharmaceutical Industries Ltd.
What Does the Report Cover?
Persistence Market Research offers a unique perspective and actionable insights on the psoriasis drugs market in its latest study, presenting historical demand assessment of 2016 - 2021 and projections for 2022 - 2031.
The research study is based on the product (topical, oral, and injectable), drug class (interleukin inhibitors, corticosteroids, anti-inflammatory, and tumor necrosis factor inhibitor), distribution channel (hospital pharmacies, retail pharmacies, and e-Commerce), and indication (guttate psoriasis, inverse psoriasis, pustular psoriasis, erythrodermic psoriasis, and plaque psoriasis), across seven key regions of the world.
Contact us:
Persistence Market Research
Address - 305 Broadway, 7th Floor, New York City,
NY 10007 United States
U.S. Ph. - +1-646-568-7751
USA-Canada Toll-free - +1 800-961-0353
Sales - sales@persistencemarketresearch.com
About us:
Persistence Market Research, as a 3rd-party research organization, does operate through an exclusive amalgamation of market research and data analytics for helping businesses ride high, irrespective of the turbulence faced on the account of financial/natural crunches.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release The Psoriasis Drugs Market to Ride on Medical Coding Software here
News-ID: 2589904 • Views: …
More Releases from Persistence Market Research
IV Fluid Transfer Drug Devices Market to Grow at a CAGR of 3.5% from 2023 to 203 …
Introduction
The IV fluid transfer drug devices market has gained significant momentum in recent years due to its vital role in ensuring safe, accurate, and sterile administration of intravenous therapies across healthcare settings. These devices are designed to facilitate efficient transfer of fluids and medications from containers to patients, minimizing the risk of contamination, dosage errors, and healthcare-associated infections. They are widely used in hospitals, ambulatory surgical centers, homecare, and specialty…
Urolithiasis Management Devices Market Set to Grow and Garner a Share of US$ 2.2 …
Introduction
The urolithiasis management devices market has witnessed significant growth in recent years, driven by the increasing prevalence of kidney stones and advancements in minimally invasive treatment options. Urolithiasis, or the formation of stones in the urinary tract, is a growing global health concern linked to changing dietary habits, sedentary lifestyles, and rising incidences of metabolic disorders such as obesity and diabetes. Management devices play a crucial role in the diagnosis,…
Endoscopic Closure Systems Market Set to Grow at a 6.7% CAGR, Crossing the US$ 4 …
Introduction
The endoscopic closure systems market has witnessed remarkable growth in recent years due to their critical role in minimally invasive surgical procedures. These systems are primarily used to close gastrointestinal perforations, resection sites, fistulas, and leaks, offering a safe and effective alternative to traditional open surgeries. Known for their efficiency, precision, and patient safety benefits, endoscopic closure systems have become indispensable in gastroenterology, bariatric surgery, oncology, and other medical specialties.
Request…
At-Home Molecular Testing Market to Reach US$16.3 Bn by 2030, Growing at 6.0% CA …
Introduction
The at-home molecular testing market has gained remarkable momentum in recent years, driven by the growing demand for accessible, convenient, and accurate diagnostic solutions. Leveraging advanced molecular technologies such as PCR and isothermal amplification, these tests enable users to detect infectious diseases, genetic conditions, and other health-related biomarkers without visiting traditional healthcare facilities. The increasing focus on patient-centric care, rising awareness about preventive health, and technological advancements in miniaturized diagnostic…
More Releases for Psoriasis
Prevalence Of Psoriasis Driving Market Growth: A Key Catalyst Accelerating Psori …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Psoriasis Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
Over the recent years, there has been a robust growth in the size of the psoriasis market. It is estimated to rise from $26.45 billion in 2024 to $28.93 billion in 2025, with a compound annual…
Psoriasis Vulgaris Market
Introduction
Psoriasis vulgaris, also known as plaque psoriasis, is the most common form of psoriasis, accounting for nearly 80-90% of all cases. It is a chronic autoimmune condition marked by red, scaly plaques that can cause significant physical discomfort and emotional distress. Affecting millions worldwide, psoriasis vulgaris is increasingly recognized as both a dermatological and systemic disease due to its association with arthritis, cardiovascular disease, and metabolic syndrome.
The global psoriasis vulgaris…
Major Growth Driver Identified in 2025 Psoriasis Market: Prevalence Of Psoriasis …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Psoriasis Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
In recent times, the size of the psoriasis market has experienced a significant increase. It is projected to escalate from $26.56 billion in 2024 to $29.5 billion in 2025, reflecting a compound annual growth rate (CAGR)…
Prevalence Of Psoriasis Driving Market Growth: Key Factor Driving The Growth In …
The Psoriasis Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Psoriasis Market Size During the Forecast Period?
The psoriasis market has seen rapid growth in recent years. It will increase from $26.56 billion in 2024 to $29.5 billion in 2025, at a…
Plaque Psoriasis to Hold 85% Share of Psoriasis Drugs Market through 2031
Psoriasis is a chronic inflammatory skin disease that occurs due to genetic disposition and environmental factors. Psoriasis is a systemic disease associated with psychological, metabolic, arthritic, and cardiovascular comorbidities. On an average, psoriasis affects around 2 - 3% of the population globally.
Plaque psoriasis, being the number one and most common indication, held nearly 85% share of the US$ 11.37 Bn psoriasis drugs market in 2021, with the market estimated to…
Global Psoriasis Market with Focus on Plaque Psoriasis: Outlook to 2020
Psoriasis is a chronic inflammatory skin disease primarily causing scaling and inflammation of skin, characterized by sharply demarcated, scaly, red skin lesions most often on the elbows, knees, scalps, hands and feet. It occurs when the body’s immune system sends out faulty signals that speed up the growth cycle of skin cells. Psoriasis has been majorly classified into Plaque psoriasis, Guttate psoriasis, Inverse psoriasis, Pustular psoriasis and Erytherodermic psoriasis. It…
